Accelerating Bioengineering Approaches for Increasing Access to New Solutions Targeting Breast Cancer Reconstructive Surgery

About This Grant

ABSTRACT There is a need in the market for a true platform technology that processes large volumes of tissues. Syntr Health Technologies has dedicated the last seven years developing the technology that can streamline tissue processing. Our FDA-cleared SyntrFuge System and SyntrFPU360, is a platform technology that can process a variety of different tissue types such as cancer tumor tissue by dissociating them into single cells to better understand tumor tissue heterogeneity, and microsizing adipose tissue for breast cancer reconstructive surgery, of which the global breast cancer reconstruction market size was $2.68 billion in 2021 and growing at a CAGR of 7.1%. Also, our platform can be used to microsize autologous adipose tissue to be used for reinjection back into the patient to treat medical conditions of the aging population such as diabetic foot ulcers and knee osteoarthritis. Syntr successfully completed an SBIR Phase I grant where we utilized micronized adipose tissue to heal diabetic ulcers in an animal model. This study had an important role in developing a treatment modality that clinically translated successfully into humans. Preliminary human clinical data shows complete diabetic foot ulcer wound closure within 3-5 weeks using autologous adipose tissue processed in the SyntrFuge System. Our platform technology for the rapid processing and/or microsizing of tissues can disrupt these markets in a major way. The seamless large volume processing of tissues using this technology in this Phase I SBIR is paramount to increase favorability in the adoption of this much needed technology in various medical fields.